Serina Therapeutics

Serina Therapeutics is a United States-based pharmaceutical company located in Huntsville, Alabama. The company positions itself around next-generation polymer science, describing its mission as turning good molecules into great medicines by unlocking the full potential of proven small molecule therapeutics. Its central asset is the POZ Platform™, a proprietary polymer platform designed to enable precise, controlled and sustained drug exposure in the body. The company's core technology is POZylation, a process that attaches its polymer to drug molecules in order to improve their pharmacokinetic behavior. According to the company, POZylation can extend delivery and administration intervals, reduce side effects and enhance the patient experience. The platform is described as customizable and versatile, and it can be dosed through intravenous (IV), subcutaneous (SC) or intramuscular (IM) routes, allowing it to address a broad range of clinical indications. Serina Therapeutics' lead candidate is SER-252, a POZylated version of apomorphine, referred to as POZ-apomorphine. Apomorphine is a well-characterized drug treatment for advanced Parkinson's disease. The company presents SER-252 as an example of the POZ Platform™ in action, with the goal of transforming infusion therapies. Specifically, Serina is developing SER-252 as a twice-weekly subcutaneous injection intended to replace complex infusion treatments that involve pumps and tubing, allowing patients to administer therapy at home and potentially remain in an "on" state around the clock. The company emphasizes a strategy of targeting known, proven drugs and enhancing them with its polymer technology rather than developing entirely new molecules. It cites decades of research, a world-class team and a clinical and regulatory strategy as the foundations of its work. Serina Therapeutics is headquartered in Huntsville, Alabama, in the United States.

Serina Therapeutics is a United States-based pharmaceutical company headquartered in Huntsville, Alabama. The company has built its identity around next-generation polymer science and the goal of improving how therapeutics perform in the body. Its stated mission is to turn good molecules into great medicines by unlocking the full potential of proven small molecule therapeutics. The foundation of the company's approach is the POZ Platform™, a proprietary polymer platform that enables precise, controlled and sustained drug exposure. The platform is based on POZylation, a technology that fundamentally improves how drugs perform in the body by extending their delivery and administration intervals, reducing side effects and enhancing the patient experience. Serina describes the platform as customizable and versatile, capable of being dosed via intravenous, subcutaneous or intramuscular routes to address a broad range of clinical indications. Serina's lead candidate is SER-252, a POZylated version of apomorphine, also called POZ-apomorphine. Apomorphine is a well-characterized drug treatment for advanced Parkinson's disease. The company is developing SER-252 with the aim of transforming infusion therapies: rather than relying on complex infusion treatments with pumps and tubing, patients could receive a single weekly injection administered at home. Serina describes the goal as offering patients a discreet, twice-weekly subcutaneous injection designed to keep them in an "on" state 24/7. The company's development strategy focuses on targeting known, proven drugs and enhancing them with its polymer technology. It cites decades of research, a world-class team and a powerful clinical and regulatory strategy as the basis for its work in transforming the future of drug optimization. Serina Therapeutics is headquartered in Huntsville, Alabama, in the United States.

A polymer science-driven drug development company focused on optimizing proven small molecule therapeutics through its proprietary POZ Platform™ and POZylation technology.

• POZ Platform™

  A proprietary polymer platform that enables precise, controlled and sustained drug exposure; customizable and versatile, and can be dosed via IV, SC or IM routes.

• POZylation

  A technology that fundamentally improves how drugs perform in the body, extending delivery and administration intervals, reducing side effects and enhancing patient experience.

• SER-252 (POZ-apomorphine)

  The company's lead candidate, a POZylated version of apomorphine, a well-characterized drug treatment for advanced Parkinson's disease; being developed as a twice-weekly subcutaneous injection to replace complex infusion treatments.

1. 1Serina Therapeuticsserinatx.com
2. 2Serina Therapeutics (United States)wikidata.org